Charles Schwab
TELO icon

Charles Schwab’s Telomir Pharmaceuticals TELO Stock Holding History

Charles Schwab’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,406
Closed -$150K – 3596
2025
Q1 		$150K Hold
46,406
– – ﹤0.01% 3289
2024
Q4 		$191K Buy
46,406
+35,556
+328% +$168K ﹤0.01% 3336
2024
Q3 		$69.7K Hold
10,850
– – ﹤0.01% 3394
2024
Q2 		$52.2K Buy
+10,850
New +$67.7K ﹤0.01% 3510

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Charles Schwab's TELO Position: Q2 2025 in Review

Charles Schwab sold out of Telomir Pharmaceuticals (TELO) in Q2 2025, closing a stake of 46,406 shares — an estimated $150K sold.

Charles Schwab first reported a position in TELO in Q2 2024 and held it in 4 quarters. The position peaked at $191K in Q4 2024. 43 funds tracked by Wall St. Rank hold TELO as of Q2 2025.

  • Charles Schwab reported no remaining Telomir Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 46,406 Telomir Pharmaceuticals shares in Q2 2025, an estimated $150K.
  • Charles Schwab first reported a position in Telomir Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Charles Schwab's Telomir Pharmaceuticals position peaked at $191K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.